MOTS-c: The Mitochondrial "Exercise Mimetic" Peptide — What the Evidence Actually Shows
A clear-eyed look at MOTS-c: strong mechanistic and rodent data for AMPK activation and insulin sensitivity, but human efficacy of the injected peptide is unproven.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13High-quality mechanistic and rodent evidence for AMPK-mediated insulin sensitivity, but human data concern the body's own MOTS-c — efficacy and safety of the injected peptide are unproven, with a Phase 2a trial only just registered.
Strong mechanism: AMPK activation and retrograde mitochondrial-to-nuclear signalling, published in serious journals.
Broad, convergent rodent base for insulin sensitivity, fat browning and metabolic homeostasis.
Human data are genetic/observational and concern the body's own MOTS-c, not an injected dose; no completed interventional trials.
No proof that injecting MOTS-c does anything clinically useful in humans.
No approved human safety profile; a Phase 2a trial will be the first to assess tolerability.
Emerging; a Phase 2a prediabetes trial has only just been registered.
Moderate for the mechanism; low for the practice of injecting it.
Unapproved anywhere; realistic supply is unregulated grey-market research chemical. FDA Category 2 nomination later withdrawn — not currently in the active Category 2 table, which is not a clearance and leaves the concerns FDA published standing.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A mitochondrial-derived peptide with a strong AMPK 'exercise-mimetic' mechanism and broad rodent data, but human evidence concerns the body's own MOTS-c — there are no completed trials of the injected peptide (a Phase 2a is only registered).
Safety snapshot
No approved human safety profile; tolerability of the injected peptide is essentially unestablished, with injection/immunogenicity and theoretical hypoglycaemia concerns.
Regulatory & legality
Unapproved anywhere; the realistic supply is unregulated grey-market 'research chemical'. The FDA lists it (spelled MOTs-C in its own table) among bulk substances nominated to Category 2 whose nominations were withdrawn, so it is not currently in the active Category 2 table; a withdrawal is not approval or clearance and the FDA still publishes the concerns it identified — including that it identified no human exposure data by any route of administration.
Where claims can exceed the evidence
High-quality mechanism and rodent data do not establish that injecting MOTS-c does anything clinically useful in humans.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
MOTS-c is one of the more genuinely interesting peptides to come out of mitochondrial biology in the last decade. It is a tiny 16-amino-acid peptide encoded not in your nuclear DNA but inside the mitochondrial genome itself, and it behaves like a hormone that links your mitochondria to whole-body metabolism [1][2]. The headline pitch in biohacking circles is "exercise in a syringe": activate the same energy-sensing pathways that training does, improve insulin sensitivity, and shift the body towards burning fat.
Here is the honest framing. The underlying biology is well-supported and published in serious journals — Cell Metabolism, Diabetologia, Aging [1][3][9][6]. But almost all the efficacy data come from mice, rats and cell culture. Direct human evidence is limited to observational and genetic studies, plus exercise studies that measure your own MOTS-c rather than an injected dose [6][7]. As of 2026 there are essentially no completed human trials showing that injecting MOTS-c does anything clinically useful. A Phase 2a trial in prediabetes (NCT07505745) has only just been registered, with results pending. So: moderate-to-strong evidence for the mechanism, emerging-and-unproven evidence for the practice.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
5-Amino-1MQ: The NNMT Inhibitor Behind the "Fat-Loss Peptide" Hype
5-Amino-1MQ is a small-molecule NNMT inhibitor with promising mouse and cell data for fat loss and muscle ageing — but zero human trials and no approval.
AICAR: The Original "Exercise in a Pill" — What the Evidence Actually Shows
AICAR is the prototype AMPK-activating exercise mimetic. The endurance hype rests entirely on mice; the only positive human data are from heart surgery.
Epithalon (Epitalon): The Telomerase Peptide, Examined
A clear-eyed look at Epitalon, the pineal tetrapeptide pitched as a telomerase activator — what the evidence actually shows, and why it is weaker than the hype suggests.
NAD+ Boosting: What the Evidence Actually Shows
NAD+ precursors reliably raise blood NAD+ and are well tolerated, but human healthspan benefits stay unproven and IV NAD+ has essentially no outcome evidence.